| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 9,256,000 | 8,544,000 | 8,080,000 | 7,776,000 | 6,675,000 |
| Sales Growth | +8.33% | +5.74% | +3.91% | +16.49% | +6.63% |
| Net Income | 2,486,000 | 2,344,000 | 2,114,000 | 2,037,000 | 1,638,000 |
| Net Income Growth | +6.06% | +10.88% | +3.78% | +24.36% | +9.20% |
Zoetis Inc Cl A (ZTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Zoetis Inc. is a leader in the animal health space with a focus on both livestock and companion animals in seven major product categories: vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. Zoetis has a diversified business, which caters to eight core species ' cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals). It directly markets its products to veterinarians and livestock producers. The outstanding growth rate in the companion animal medicines, vaccines and diagnostics sector is being driven by economic development, related increases in disposable income and a rise in pet ownership and spending on pet care.Zoetis has been working on strengthening its product portfolio through acquisitions and deals.
Fiscal Year End Date: 12/31